Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 961,696
  • Shares Outstanding, K 62,529
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -198,970 K
  • EBIT $ -185 M
  • EBITDA $ -171 M
  • 60-Month Beta 0.75
  • Price/Sales 63.31
  • Price/Cash Flow N/A
  • Price/Book 5.10

Options Overview Details

View History
  • Implied Volatility 154.79% (+24.94%)
  • Historical Volatility 185.52%
  • IV Percentile 76%
  • IV Rank 35.60%
  • IV High 302.43% on 02/17/26
  • IV Low 73.19% on 10/03/25
  • Expected Move (DTE 4) 1.73 (11.22%)
  • Put/Call Vol Ratio 1.60
  • Today's Volume 10,805
  • Volume Avg (30-Day) 5,262
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 278,007
  • Open Int (30-Day) 288,189
  • Expected Range 13.65 to 17.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.88
  • Number of Estimates 4
  • High Estimate $-0.79
  • Low Estimate $-1.03
  • Prior Year $-0.82
  • Growth Rate Est. (year over year) -7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.21 +16.43%
on 04/10/26
18.98 -18.97%
on 03/11/26
-2.88 (-15.77%)
since 03/10/26
3-Month
8.73 +76.17%
on 03/03/26
28.48 -46.00%
on 02/03/26
-9.94 (-39.26%)
since 01/09/26
52-Week
8.42 +82.66%
on 04/11/25
71.50 -78.49%
on 10/28/25
+6.81 (+79.46%)
since 04/10/25

Most Recent Stories

More News
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

LOS ANGELES , April 12, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE ) for violations...

QURE : 15.38 (-5.64%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , April 12, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure"...

QURE : 15.38 (-5.64%)
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK , April 12, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and...

QURE : 15.38 (-5.64%)
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V. - QURE

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 13, 2026 ...

QURE : 15.38 (-5.64%)
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and...

QURE : 15.38 (-5.64%)
QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options

QURE : 15.38 (-5.64%)
QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit

QURE : 15.38 (-5.64%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised...

QURE : 15.38 (-5.64%)
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears

SAN FRANCISCO , April 7, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes...

QURE : 15.38 (-5.64%)
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

NEW YORK , April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE) .

QURE : 15.38 (-5.64%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 19.91
2nd Resistance Point 18.13
1st Resistance Point 16.76
Last Price 15.38
1st Support Level 13.61
2nd Support Level 11.83
3rd Support Level 10.46

See More

52-Week High 71.50
Fibonacci 61.8% 47.40
Fibonacci 50% 39.96
Fibonacci 38.2% 32.52
Last Price 15.38
52-Week Low 8.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.